Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

What Was Tested

Researchers studied Liraglutide and Dulaglutide in this randomized controlled trial publication.

Who Took Part

By PubMed's age tags, the people studied were middle-aged adults, both men and women.

Participants and investigators were not masked to treatment allocation.

How the Study Was Run

The researchers set it up as a randomized, open-label and parallel-group study.

Random assignment meant chance, not the researchers, decided who got Liraglutide and who got the comparison, which limits bias.

Everyone knew when Liraglutide was being given (open label), which is simpler to run but leaves more room for expectations to affect what is reported.

The Liraglutide group and the comparison group ran side by side rather than switching.

The researchers did a phase 3, randomised, open-label, parallel-group study at 62 sites in nine countries between June 20, 2012, and Nov 25, 2013.

Randomisation was done according to a computer-generated random sequence with an interactive voice response system.

Safety data were collected for a further 4 weeks' follow-up.

Analysis was by intention to treat.

This study is registered with ClinicalTrials.gov, number NCT01624259.

What Was Measured

Topics PubMed links to this paper include Analysis of Variance, Blood Glucose, Diabetes Mellitus, Type 2, Fasting, Glucagon-Like Peptide 1, Glucagon-Like Peptides and Glycated Hemoglobin.

What This Means in Plain Language

The paper is a randomized, open-label and parallel-group study of Liraglutide and Dulaglutide.

The abstract goes on to report its results in about 6 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 2014 (Lancet (London, England)), a journal based in England.

More context: the Liraglutide compound page and the Dulaglutide compound page.